Physician profile
Waldemar Klimek
NPI 1235101916
$2,803.03
in general payments reported to CMS, 2019-2025
25 companies · $610 in 2025
The $610 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $137 · 2021: $150 · 2022: $404 · 2023: $562 · 2024: $529 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,495 · Education: $205.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,494.64 |
| Education | $205.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $398.08 | 2019-2025 | |
| Astellas Pharma US INC | $347.87 | 2023-2025 | Veozah, Myrbetriq |
| Sumitomo Pharma America, INC. | $300.38 | 2023-2025 | Myfembree, Gemtesa |
| Millicent US INC | $274.62 | 2024-2025 | Intrarosa, Femring, Femlyv |
| Pfizer INC. | $265.03 | 2019-2025 | |
| Exeltis, USA INC. | $234.54 | 2019-2025 | Slynd |
| Duchesnay USA Incorporated | $163.82 | 2019 | |
| Amgen INC. | $140.15 | 2022-2024 | Prolia, Evenity |
| Mayne Pharma Commercial LLC | $132.51 | 2023-2025 | |
| Therapeuticsmd, INC. | $90.01 | 2019-2022 | |
| Allergan, INC. | $74.16 | 2019-2022 | |
| Coopersurgical, INC. | $65.00 | 2022-2024 | Paragard T 380a, Paragard T 380a |
| Bayer Healthcare Pharmaceuticals INC. | $58.98 | 2019-2021 | |
| Hologic Sales and Service, LLC | $39.53 | 2024-2025 | Omni Hysteroscope, Myosure Tissue Removal Device |
| Ge Healthcare | $29.57 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $27.14 | 2025 | Zurzuvae |
| Laborie Medical Technologies Corp. | $25.48 | 2025 | Eclipse |
| Organon LLC | $24.89 | 2025 | Nexplanon |
| Scynexis, INC. | $17.43 | 2022 | |
| Agile Therapeutics, INC. | $16.67 | 2022 | |
| Lupin INC. | $16.37 | 2019 | |
| Merck Sharp & Dohme LLC | $16.08 | 2024 | Gardasil 9, Gardasil |
| Myovant Sciences INC. | $15.60 | 2022 | |
| Vertical Pharmaceuticals, LLC | $14.99 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Waldemar Klimek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.